Contact
searchSearch
HMP Global
Login

News

News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology
News
Circulating Tumor DNA-Guided Adjuvant Atezolizumab Significantly Improves Survival Otucomes in Bladder Cancer
10/20/2025
Stephanie Holland
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by...
10/20/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
Nicholas James, MD, PhD
Videos
Clinical Impact of Upfront Multiparametric MRI on Staging Accuracy and Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Nicholas James, MD
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD,...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use